scispace - formally typeset
Search or ask a question
Author

You Lina

Bio: You Lina is an academic researcher from Fifth Affiliated Hospital of Xinjiang Medical University. The author has contributed to research in topics: Hepatocellular carcinoma & Transcatheter arterial chemoembolization. The author has an hindex of 3, co-authored 7 publications receiving 18 citations.

Papers
More filters
Journal Article
TL;DR: It was shown that metronomic S-1 chemotherapy plus TACE may be a promising treatment of BCLC Stage B HCC refractory to TACE and associated with a better but not statistically significant TTP, RR and OS.
Abstract: Purpose To assess the efficacy and safety of metronomic S-1 chemotherapy combination with transcatheter arterial chemoembolization (TACE) for the treatment of Barcelona Clinic Liver Cancer (BCLC) Stage B hepatocellular carcinoma (HCC) refractory to TACE. Methods Twenty six patients met the eligibility criteria and were enrolled. TACE was performed on day 1, and metronomic S-1 chemotherapy on days 2-15. Tumor assessment was performed one month later. The primary endpoints were time to progression (TTP) and adverse events (AE). Results Twenty six patients in total received 176 TACE interventions. There were 101 TACE interventions in 15 patients of metronomic S-1 chemotherapy plus TACE (TS) and 75 in 11 patients of TACE monotherapy (TM). Fifteen TS patients received a total of 55 cycles of treatment with S-1, with a median of 4 cycles (range 2-6). The total dose of S-1 was 6165 mg per day in 15 patients (average 120 mg, range 100-125). Median TTP and overall survival (OS) of TS group were 6 months (95% CI, 4.7-7.3) and 17 months (95% CI, 15.6-18.4), respectively, while for the TM group were 4 months (95% CI, 2.4-5.6) and 15 months (95% CI, 9.2-20.8), respectively. Though there were higher tumor response rate (RR) and disease control rates (DCRs) in patients with TS, no significant differences were detected. Both treatment approaches were tolerable with low grade AE. Conclusions In the present study, metronomic S-1 chemotherapy plus TACE in the present study was tolerable and associated with a better but not statistically significant TTP, RR and OS. It showed that metronomic S-1 chemotherapy plus TACE may be a promising treatment of BCLC Stage B HCC refractory to TACE.

8 citations

Journal ArticleDOI
TL;DR: TACE plus S-1 in the present analysis was tolerable and associated with an interesting TTP and OS, and may be used as a new treatment method to BCLC Stage B HCC refractory to TACE.
Abstract: Aim of the study To assess the efficacy and safety of transcatheter arterial chemoembolization (TACE) plus S-1 for the treatment of Barcelona Clinic Liver Cancer (BCLC) Stage B HCC refractory to TACE. Material and methods 26 patients meeting the eligibility criteria were enrolled. TACE was given on day 1, and S-1 on days 2-15. Tumor assessment was performed one month later according to mRECIST. The primary endpoints were TTP and OS. Results Twenty-six patients received 176 TACE interventions in all. Fifteen patients of TACE plus S-1 received a total of 55 cycles of treatment of S-1, with a median of 4 cycles (range, 2-6). The total dose of S-1 was 6165 mg per day, while average was 120 mg (range, 100-125 mg) for 15 patients of TACE plus S-1. Median TTP and OS of TACE plus S-1 were 6 months (95% CI: 4.7-7.3) and 18 months (95% CI: 15.3-24.7), respectively, while TACE monotherapy was 4 months (95% CI: 2.4-5.6) and 13 months (95% CI: 9.8-16.2), respectively, and significant differences were detected. Though there were higher DCRs in patients of TACE plus S-1, no significant differences were detected. A total of 612 adverse events occurred during the course of the treatment, 367 in TACE plus S-1 and 245 in TACE mono-therapy. There were significant differences to anorexia and nausea, but they were tolerable. Conclusions TACE plus S-1 in the present analysis was tolerable and associated with an interesting TTP and OS. TACE plus S-1 may be used as a new treatment method to BCLC Stage B HCC refractory to TACE.

7 citations

Journal ArticleDOI
TL;DR: Current evidence from the available clinical studies suggests that S-1 may be an effective and tolerable treatment for advanced HCC and further clinical studies are warranted to further investigate this treatment option.
Abstract: Hepatocellular carcinoma (HCC) is the most common liver neoplasm worldwide. Based on its potent inhibition of dihydropyrimidine dehydrogenase (DPD), S-1 is expected to be more active than other fluoropyrimidines against HCC with DPD activity. This systematic review was aimed to assess the efficacy and safety of S-1 for treatment of advanced HCC. PubMed, the Cochrane Library, EMBA-SE, and ClinicalTrials.gov were searched using the terms "Hepatocellular Carcinoma" or "HCC" or "Hepatoma" or "Liver cancer" and ''S-1''. Outcomes of main interest included overall survival (OS) and toxicities. We identified four studies of S-1 treatment alone from 1059 references, including a total of 272 patients. There were two original articles and two conference abstracts. The percentage of male patients ranged from 88 to 91.3% and median age ranged from 59 to 70 years. Median OS ranged from 8.6 to 16.5 months. The incidences of toxicity of more than 50% were thrombocytopaenia and fatigue. According to the original description, toxicities were acceptable. The current evidence from the available clinical studies suggests that S-1 may be an effective and tolerable treatment for advanced HCC. Further clinical studies are warranted to further investigate this treatment option.

4 citations

Journal Article
TL;DR: This systematic review suggests that S-1 plus sorafenib showed modest clinical efficacy and tolerable toxicity profile in patients with advanced HCC.
Abstract: Purpose To assess the efficacy and safety of S-1 plus sorafenib for the treatment of advanced hepatocellular carcinoma (HCC). Methods PubMed, the Cochrane Library, EMBASE, and ClinicalTrials.gov were searched using the terms "Hepatocellular Carcinoma" or "HCC" or "Hepatoma" or "Liver cancer" and "S-1" and "Sorafenib" or "Nexavar". Outcomes of main interest included overall survival (OS) and toxicities. Results We identified 2 studies of S"1 plus sorafenib from 77 references that included a total of 65 patients. The percentage of male patients ranged from 70.0 to 89.5%. Median age was 59.2 years and ranged from 48.0 to 65.5 years. The percentage of hepatitis B virus ranged from 23.1 to 90.0%. The recommended dose of S-1 and sorafenib was 80 or 64 mg/m2/day and 800 mg/day, respectively and treatment was administered orally on days 1-14 and days 1-21, respectively. Median OS were 10.4 and 10.5 months, respectively. The incidence of all-grade toxicities of more than 30% were hand"foot syndrome (HFS) and rash. The incidence of grade 3/4 toxicities more than 5% were thrombocytopenia, elevated AST/ALT and hyperbilirubinemia. Conclusion This systematic review suggests that S-1 plus sorafenib showed modest clinical efficacy and tolerable toxicity profile in patients with advanced HCC. The recommended dose of S-1 and sorafenib was 80 or 64 mg/m2/day and 800 mg/day, respectively.

2 citations

Patent
16 Jan 2018
TL;DR: In this paper, the authors describe a puncture cone needle assembly which consists of a sleeve, a first puncture needle and a second puncture-cone needle, and when an intestinal tube or a blood vessel exists in front of the punctureneedles, the damage to intestinal tubes or blood vessels can be relieved in the puncturing process.
Abstract: The invention relates to a puncture cone needle assembly which comprises a sleeve, a first puncture needle and a second puncture needle. The puncture end of the first puncture needle is of a camberedsurface structure, and the puncture end of the second puncture needle is of a sharp pointed structure; the outer side wall of the first puncture needle and the outer side wall of the second puncture needle are matched with the inner side wall of the sleeve; the first puncture needle is fixed to the interior of the sleeve in a pluggable mode, and the puncture end of the first puncture needle stretches out from one end of the sleeve; or the second puncture needle is fixed to the interior of the sleeve in a pluggable mode, and the puncture end of the second puncture needle stretches out from oneend of the sleeve. When the puncture cone needle starts puncturing, the second puncture needle punctures sin and other tissue; when an intestinal tube or a blood vessel exists in front of the punctureneedles, the second puncture needle can be pulled out and replaced with the first puncture needle, and due to the fact that the end of the puncture section of the first puncture needle is of the cambered surface structure, and the damage to intestinal tubes or blood vessels can be relieved in the puncturing process.

1 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: The pathogenesis of HCC is discussed in relation to its various recent treatment methodologies using nanodelivery of monoclonal antibodies (mAbs), small molecules, miRNAs and peptides, with a broad overview of the pathogenic of the disease and treatment efficacy.

204 citations

Journal ArticleDOI
TL;DR: One patient with advanced hepatocellular carcinoma, who received apatinib combined with transhepatic arterial chemotherapy and embolization, and chemotherapy respectively, was confirmed as partial response by the Response Evaluation Criteria in Solid Tumors (RECIST), indicating that apatin ib may be a superior choice for HCC patients.
Abstract: // Peisi Kou 1,2,* , Yan Zhang 2,* , Wenbo Shao 4 , Hui Zhu 2 , Jingze Zhang 2 , Haiyong Wang 2 , Li Kong 2 and Jinming Yu 2,3,1 1 Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China 2 Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China 3 School of Medicine and Life Sciences, University of Jinan - Shandong Academy of Medical Sciences, Jinan, China 4 Department of Intervention, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China * These authors have contributed equally to this work Correspondence to: Jinming Yu, email: // Keywords : hepatocellular carcinoma, apatinib, targeted therapy Received : September 06, 2016 Accepted : January 04, 2017 Published : January 18, 2017 Abstract Apatinib is a novel and highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. Previous studies have suggested that apatinib is safe and effective in some solid tumors. We report one case with advanced hepatocellular carcinoma (HCC), who received apatinib combined with transhepatic arterial chemotherapy and embolization (TACE), and chemotherapy respectively. TACE was administered three times once a month, using lipiodol 10ml, oxaliplatin 150mg, and tegafur 1g. The dose of apatinib was 500 mg/d from day 4 to 24. After TACE, the patient received chemotherapy of regimen FOLFOX4, oxaliplatin intravenously at 85 mg/m 2 on day 1, calcium levofolinate 200 mg/m 2 on day 1 and 2, 5-fluorouracil 400 mg/m 2 intravenously and 5-fluorouracil 600 mg/m 2 intravenously pumped for 22h on day 1 and 2, cycled every two weeks for seven cycles. He took concurrently apatinib with a dose of 500mg daily from 1 to 10 days per cycle. He was confirmed as partial response (PR) by the Response Evaluation Criteria in Solid Tumors (RECIST). The level of serum alpha-fetoprotein (AFP) decreased from 60500 ng/ml to 12.7 ng/ml, and the progression free survival (PFS) time was more than eight months. It indicated that apatinib may be a superior choice for HCC patients.

35 citations

Journal ArticleDOI
TL;DR: MiR-133a may be a potential prognostic biomarker and may thus be a new therapy in HCC and it is verified that overexpression of miR- 133a suppressed biological behaviour of HCC through TGF-β/Smad3 signaling pathway.

27 citations

Journal ArticleDOI
TL;DR: TACE can significantly improve local response, increase cumulative survival rate, and prolong the survival duration of patients with HCC and grades I/II PVTT, whereas the efficacy of TACE for patients with grades III/IV PVTT should be further verified, although their local responses were improved.
Abstract: Objectives To explore the efficacy and influencing factors of transarterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC) combined with portal vein tumor thrombosis (PVTT). Materials and methods The clinical data of 3,126 consecutive patients who suffered from advanced HCC and underwent TACE were retrospectively analyzed. A total of 685 patients had a combination of HCC and PVTT. Of these patients, 475 were treated with TACE (Group A) and 210 were given a supportive care (Group B). The local response and overall survival of the two groups were observed and compared, and the influencing factors were examined through Cox regression analysis. Results The median survival time and cumulative survival rate at 6, 12, and 24 months of Group A were higher than those of Group B (P=0.002). Multiple Cox regression analysis revealed that Child-Pugh classes and PVTT grades were the independent prognostic factors affecting a patient's survival. Stratified analysis demonstrated that the survival time of patients diagnosed with grades I/II PVTT and treated with TACE was superior to that of patients provided with supportive care (P=0.001), but the survival time of patients with grades III/IV PVTT with or without TACE did not significantly differ (P=0.662). Conclusion TACE can significantly improve local response, increase cumulative survival rate, and prolong the survival duration of patients with HCC and grades I/II PVTT, whereas the efficacy of TACE for patients with grades III/IV PVTT should be further verified, although their local responses were improved. Child-Pugh classes and PVTT grades are essential factors influencing patient prognosis.

15 citations